We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- GRE: where it all began
- Prevalence of GRE in the UK
- GRE bacteraemias, EARSS 2008
- Vancomycin resistant enterococci in the US
- GRE are a localised problem in the UK
- Enterococci as opportunist pathogens
- Risk factors for GRE infection
- The clinical problem with GRE - mutliresistance
- Enterococcus species
- Glycopeptide resistance in enterococci
- Characteristics of glycopeptide resistance
- GRE: primarily E. faecium with VanA
- Glycopeptide action and resistance
- GRE...all because of one critical H-bond
- Regulation of glycopeptide resistance (VanA)
- Cell wall synthesis in GRE
- Glycopeptide dependent enterococci
- Cell wall synthesis in resistant enterococci
- Resistant isolates
- PFGE analysis: the "gold standard" method
- A national epidemic of GRE in the UK?
- Avoparcin and VanA resistance
- MLST of 720 E. faecium isolates
- Hospital-adapted lineages
- Virulence of E. faecalis
- Resistance genes and elements
- Genetic exchange in enterococci
- The van gene clusters of enterococci
- Transposons carry van gene clusters
- A national epidemic of VanA elements?
- VanA elements in the UK
- Origins of resistant enterococci affecting humans
- Diversity among VanA elements
- Transfer of van genes beyond enterococci
- VanA MRSA has arrived
- Glycopeptide MICs for two VRSA strains
- Poor detection of some VRSA
- Glycopeptide-intermediate S. aureus (GISA)
- Biochemical basis of resistance in GISA
- Resistance to new agents: the red queen theory
- Quinupristin-dalfopristin vs. enterococci
- 'Q-D' resistance mechanisms in enterococci
- Linezolid resistance in enterococci
- Development of linezolid resistance
- Linezolid resistance - summary
- Daptomycin: a cyclic lipopeptide
- Daptomycin: mechanism of action
- Daptomycin: resistance issues, E. faecium
- Second generation glycopeptides (1)
- Vancomycin's and teicoplanin's modes of action
- Second generation glycopeptides (2)
- In vitro activity vs. enterococci
- Telavancin vs. GRE
- Potential for a better anti GRE glycopeptide
- Epidemiology of GRE
- Acknowledgements
Topics Covered
- Original description
- Rates of resistance
- Types of infections
- Risk factors
- Resistance profiles of major species
- Types of vancomycin resistance
- Resistance mechanism
- Cell wall structure
- Glycopeptide dependence
- Epidemiological investigation
- Virulence factors
- Van gene clusters
- VanA S. aureus
- VISA
- 'New' anti-GRE agents and resistance
- New glycopeptides
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Woodford, N. (2009, December 31). Glycopeptide-resistant enterococci [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/XYOS1843.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Neil Woodford has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.